Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295990 | 0.79 | MTNR1A (0.42) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL19774297 | 0.78 | MTNR1A (0.47) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL424121 | 0.75 | MTNR1A (0.45) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL4130897 | 0.75 | MTNR1A (0.45) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL5066 | 0.75 | MTNR1A (0.42) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL6575709 | 0.75 | MTNR1A (0.45) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL8771344 | 0.75 | MTNR1A (0.42) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL483233 | 0.75 | SMYD3 (0.48) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL13305784 | 0.75 | MTNR1A (0.45) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL2697405 | 0.75 | MTNR1A (0.45) | MTNR1ASMYD3NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | claimed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | claimed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | claimed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | claimed |
| US-6576628-B1 | Matrix metalloprotease inhibitors; arthritis, corneal ulcers, arteriosclerosis | ROCHE DIAGNOSTICS GMBH (DE) | 2003-06-10 | — | — | US | claimed |
| US-6569847-B1 | Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease | NAEJA PHARMACEUTICALS INC. (CA) | 2003-05-27 | — | — | US | claimed |
| EP-0765314-B1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| JP-2002544121-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | claimed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | claimed |
| EP-1165506-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-01-02 | — | — | EP | claimed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | claimed |
| WO-2000059881-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2000-10-12 | — | — | WO | claimed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | claimed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | claimed |
| EP-0122627-A2 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-24 | — | — | EP | claimed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-3998641-A | A 2-CYCLOTETRAMETHYLENE SULFONE-CONTAINING BETA-KETOACETANILIDE | AGFA-GEVAERT, A.G. (DT) | 1976-12-21 | — | — | US | disclosed |
| US-RE28760-E | Photographic element including superimposed silver halide layers of different speeds | EASTMAN KODAK COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | MTNR1A 197/4885SMYD3 2996/4885NPC1 1819/4885 |
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | MTNR1A 334/4885SMYD3 4617/4885NPC1 2978/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MTNR1A 802/4885SMYD3 4269/4885NPC1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.